92 related articles for article (PubMed ID: 27797265)
21. Relationship between human epididymal protein 4 and depth of tumor invasion, postoperative recurrence, and metastasis of epithelial epithelial ovarian cancer.
Li Y; Yu C; Li H; Feng Y; Fan P; Chen X
Asia Pac J Clin Oncol; 2024 Apr; ():. PubMed ID: 38615275
[TBL] [Abstract][Full Text] [Related]
22. Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer.
James NE; Chichester C; Ribeiro JR
Front Oncol; 2018; 8():124. PubMed ID: 29740539
[TBL] [Abstract][Full Text] [Related]
23. Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer
Ribeiro JR; Gaudet HM; Khan M; Schorl C; James NE; Oliver MT; DiSilvestro PA; Moore RG; Yano N
Front Oncol; 2017; 7():332. PubMed ID: 29404274
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes.
James NE; Beffa L; Oliver MT; Borgstadt AD; Emerson JB; Chichester CO; Yano N; Freiman RN; DiSilvestro PA; Ribeiro JR
Oncotarget; 2019 May; 10(36):3315-3327. PubMed ID: 31164954
[TBL] [Abstract][Full Text] [Related]
25. Cancer Marker Immunosensing through Surface-Enhanced Photoluminescence on Nanostructured Silver Substrates.
Geka G; Kanioura A; Kochylas I; Likodimos V; Gardelis S; Dimitriou A; Papanikolaou N; Chatzantonaki K; Charvalos E; Economou A; Kakabakos S; Petrou P
Nanomaterials (Basel); 2023 Dec; 13(24):. PubMed ID: 38132997
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites.
den Ouden JE; Zaman GJR; Dylus J; van Doornmalen AM; Mulder WR; Grobben Y; van Riel WE; de Hullu JA; Buijsman RC; van Altena AM
Oncotarget; 2020 Dec; 11(49):4570-4581. PubMed ID: 33346216
[TBL] [Abstract][Full Text] [Related]
27. Use of Sensor Array Analysis to Detect Ovarian Cancer through Breath, Urine, and Blood: A Case-Control Study.
Angioli R; Santonico M; Pennazza G; Montera R; Luvero D; Gatti A; Zompanti A; Finamore P; Incalzi RA
Diagnostics (Basel); 2024 Mar; 14(5):. PubMed ID: 38473033
[TBL] [Abstract][Full Text] [Related]
28. Epithelial ovarian cancer: An overview.
Desai A; Xu J; Aysola K; Qin Y; Okoli C; Hariprasad R; Chinemerem U; Gates C; Reddy A; Danner O; Franklin G; Ngozi A; Cantuaria G; Singh K; Grizzle W; Landen C; Partridge EE; Rice VM; Reddy ES; Rao VN
World J Transl Med; 2014 Apr; 3(1):1-8. PubMed ID: 25525571
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer.
Uno M; Matsuo R; Maezawa N; Kato T
Obstet Gynecol Sci; 2023 Jul; 66(4):290-299. PubMed ID: 37380167
[TBL] [Abstract][Full Text] [Related]
30. Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine.
Kight EC; Hussain I; Bowden AK; Haselton FR
Sci Rep; 2021 Nov; 11(1):21945. PubMed ID: 34754053
[TBL] [Abstract][Full Text] [Related]
31. DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway.
Liu SB; Lin XP; Xu Y; Shen ZF; Pan WW
J Ovarian Res; 2018 Oct; 11(1):90. PubMed ID: 30336783
[TBL] [Abstract][Full Text] [Related]
32. Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer.
Innao P; Pothisuwan M; Pengsa P
Asian Pac J Cancer Prev; 2016; 17(9):4483-4486. PubMed ID: 27797265
[TBL] [Abstract][Full Text] [Related]
33. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
[TBL] [Abstract][Full Text] [Related]
34. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
35. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
[TBL] [Abstract][Full Text] [Related]
36. Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
El Bairi K; Afqir S; Amrani M
Curr Drug Targets; 2020; 21(10):1026-1033. PubMed ID: 32334501
[TBL] [Abstract][Full Text] [Related]
37. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.
Capriglione S; Luvero D; Plotti F; Terranova C; Montera R; Scaletta G; Schirò T; Rossini G; Benedetti Panici P; Angioli R
Med Oncol; 2017 Aug; 34(9):164. PubMed ID: 28825178
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
